Postal voting EQL Pharma AGM 2020

EQL Pharma AB (publ), 556713-3425, Annual General Meeting will take place on Thursday, August 27th, 2020 at. 4 PM at EQL Pharma AB's offices, Stortorget 1 Lund.

According to the Act (2020: 198) on temporary exemptions to facilitate the conduct of general and association meetings, the Board of Directors of EQL Pharma AB (corporate identity number 556713-3425) (“EQL Pharma”) has decided that shareholders shall be able to exercise their voting rights before the Annual General Meeting per mail.

If shareholders wish to exercise their voting rights by postal vote before the Annual General Meeting, a complete form, including any appendices, must be received by EQL Pharma no later than 25th of August 2020 at 4 pm.

Instructions for procedures and forms for postal voting are available on the company's website: http://eqlpharma.com/en/investors/annual-general-meeting/

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 18 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2020 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 9 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.